Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma
Background: The therapeutic effectiveness of dupilumab for severe asthma in real-world settings is yet to be prospectively investigated across multiple institutions, and uncertainties persist regarding predictive factors for its effectiveness. We aimed to assess the effectiveness of dupilumab and id...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Allergology International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S132389302400087X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560560338993152 |
|---|---|
| author | Kenji Mizumura Yasuhiro Gon Norihiro Harada Shiho Yamada Asami Fukuda Ryosuke Ozoe Shuichiro Maruoka Sumiko Abe Kazuhisa Takahashi Akihiko Tanaka Hironori Sagara Taisuke Akamatsu Toshihiro Shirai Katsunori Masaki Koichi Fukunaga Konomi Kobayashi Hiroyuki Nagase Nobuaki Miyahara Arihiko Kanehiro Noboru Kitamura Naruhiko Sugihara Fumio Kumasawa Junko Terada-Hirashima Masayuki Hojo Kazuyuki Chibana Etsuko Tagaya |
| author_facet | Kenji Mizumura Yasuhiro Gon Norihiro Harada Shiho Yamada Asami Fukuda Ryosuke Ozoe Shuichiro Maruoka Sumiko Abe Kazuhisa Takahashi Akihiko Tanaka Hironori Sagara Taisuke Akamatsu Toshihiro Shirai Katsunori Masaki Koichi Fukunaga Konomi Kobayashi Hiroyuki Nagase Nobuaki Miyahara Arihiko Kanehiro Noboru Kitamura Naruhiko Sugihara Fumio Kumasawa Junko Terada-Hirashima Masayuki Hojo Kazuyuki Chibana Etsuko Tagaya |
| author_sort | Kenji Mizumura |
| collection | DOAJ |
| description | Background: The therapeutic effectiveness of dupilumab for severe asthma in real-world settings is yet to be prospectively investigated across multiple institutions, and uncertainties persist regarding predictive factors for its effectiveness. We aimed to assess the effectiveness of dupilumab and identify predictors of its effectiveness in real-world settings using two type-2 biomarkers: FeNO concentration and blood eosinophil count. Methods: This prospective multicenter study included 103 patients with severe asthma. Exacerbations and respiratory functions were monitored for 24 weeks. Asthma control was evaluated using the Asthma Control Questionnaire-5. Clinical symptoms and their impact on cough and sputum were assessed using the Cough and Sputum Assessment Questionnaire (CASA-Q). Subgroup analyses of type-2 biomarkers were conducted based on FeNO levels and blood eosinophil counts at baseline. Results: Treatment with dupilumab led to a reduction in exacerbations and enhancement in asthma control, FEV1, and CASA-Q scores. FEV1 improvement was correlated with enhancement in the sputum domain of the CASA-Q. Patients exhibiting elevated FeNO levels and blood eosinophil counts demonstrated more significant enhancements in FEV1. CASA-Q sputum domain scores were significantly higher in the group with elevated eosinophil counts. Regression analysis revealed that FeNO levels and blood eosinophil counts are significant predictors of FEV1 improvement, with blood eosinophil counts also predicting sputum improvement in patients treated with dupilumab. Conclusions: Type-2 biomarkers may act as indicators of improvement in FEV1 and sputum outcomes among patients with severe asthma undergoing dupilumab treatment in real-world settings. |
| format | Article |
| id | doaj-art-6a9277efefff408fae7a6dc9171cca7d |
| institution | Kabale University |
| issn | 1323-8930 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Allergology International |
| spelling | doaj-art-6a9277efefff408fae7a6dc9171cca7d2025-01-04T04:56:06ZengElsevierAllergology International1323-89302025-01-01741144155Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthmaKenji Mizumura0Yasuhiro Gon1Norihiro Harada2Shiho Yamada3Asami Fukuda4Ryosuke Ozoe5Shuichiro Maruoka6Sumiko Abe7Kazuhisa Takahashi8Akihiko Tanaka9Hironori Sagara10Taisuke Akamatsu11Toshihiro Shirai12Katsunori Masaki13Koichi Fukunaga14Konomi Kobayashi15Hiroyuki Nagase16Nobuaki Miyahara17Arihiko Kanehiro18Noboru Kitamura19Naruhiko Sugihara20Fumio Kumasawa21Junko Terada-Hirashima22Masayuki Hojo23Kazuyuki Chibana24Etsuko Tagaya25Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan; Corresponding author. Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo 173-8610, Japan.Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, JapanDepartment of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Juntendo University, Tokyo, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, JapanDepartment of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Juntendo University, Tokyo, JapanDepartment of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Juntendo University, Tokyo, JapanDivision of Respiratory Medicine and Allergology, Department of Medicine, School of Medicine, Showa University, Tokyo, JapanDivision of Respiratory Medicine and Allergology, Department of Medicine, School of Medicine, Showa University, Tokyo, JapanDepartment of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, JapanDepartment of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, JapanDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, JapanDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, JapanDivision of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, JapanDivision of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medical Technology, Okayama University Academic Field of Health Sciences, Okayama, JapanSocial Medical Corporation Foundation of St. Francis Himeji St. Mary's Hospital, Hyogo, JapanJinyu Clinic, Tokyo, JapanJinyu Clinic, Tokyo, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan; Division of Respiratory Medicine, Akabane Central General Hospital, Tokyo, JapanDepartment of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, JapanDepartment of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, JapanDepartment of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Tochigi, JapanDepartment of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, JapanBackground: The therapeutic effectiveness of dupilumab for severe asthma in real-world settings is yet to be prospectively investigated across multiple institutions, and uncertainties persist regarding predictive factors for its effectiveness. We aimed to assess the effectiveness of dupilumab and identify predictors of its effectiveness in real-world settings using two type-2 biomarkers: FeNO concentration and blood eosinophil count. Methods: This prospective multicenter study included 103 patients with severe asthma. Exacerbations and respiratory functions were monitored for 24 weeks. Asthma control was evaluated using the Asthma Control Questionnaire-5. Clinical symptoms and their impact on cough and sputum were assessed using the Cough and Sputum Assessment Questionnaire (CASA-Q). Subgroup analyses of type-2 biomarkers were conducted based on FeNO levels and blood eosinophil counts at baseline. Results: Treatment with dupilumab led to a reduction in exacerbations and enhancement in asthma control, FEV1, and CASA-Q scores. FEV1 improvement was correlated with enhancement in the sputum domain of the CASA-Q. Patients exhibiting elevated FeNO levels and blood eosinophil counts demonstrated more significant enhancements in FEV1. CASA-Q sputum domain scores were significantly higher in the group with elevated eosinophil counts. Regression analysis revealed that FeNO levels and blood eosinophil counts are significant predictors of FEV1 improvement, with blood eosinophil counts also predicting sputum improvement in patients treated with dupilumab. Conclusions: Type-2 biomarkers may act as indicators of improvement in FEV1 and sputum outcomes among patients with severe asthma undergoing dupilumab treatment in real-world settings.http://www.sciencedirect.com/science/article/pii/S132389302400087XAsthmaDupilumabEosinophilFractional exhaled nitric oxideSputum |
| spellingShingle | Kenji Mizumura Yasuhiro Gon Norihiro Harada Shiho Yamada Asami Fukuda Ryosuke Ozoe Shuichiro Maruoka Sumiko Abe Kazuhisa Takahashi Akihiko Tanaka Hironori Sagara Taisuke Akamatsu Toshihiro Shirai Katsunori Masaki Koichi Fukunaga Konomi Kobayashi Hiroyuki Nagase Nobuaki Miyahara Arihiko Kanehiro Noboru Kitamura Naruhiko Sugihara Fumio Kumasawa Junko Terada-Hirashima Masayuki Hojo Kazuyuki Chibana Etsuko Tagaya Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma Allergology International Asthma Dupilumab Eosinophil Fractional exhaled nitric oxide Sputum |
| title | Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma |
| title_full | Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma |
| title_fullStr | Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma |
| title_full_unstemmed | Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma |
| title_short | Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma |
| title_sort | predicting dupilumab effectiveness with type 2 biomarkers a real world study of severe asthma |
| topic | Asthma Dupilumab Eosinophil Fractional exhaled nitric oxide Sputum |
| url | http://www.sciencedirect.com/science/article/pii/S132389302400087X |
| work_keys_str_mv | AT kenjimizumura predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT yasuhirogon predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT norihiroharada predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT shihoyamada predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT asamifukuda predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT ryosukeozoe predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT shuichiromaruoka predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT sumikoabe predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT kazuhisatakahashi predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT akihikotanaka predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT hironorisagara predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT taisukeakamatsu predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT toshihiroshirai predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT katsunorimasaki predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT koichifukunaga predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT konomikobayashi predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT hiroyukinagase predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT nobuakimiyahara predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT arihikokanehiro predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT noborukitamura predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT naruhikosugihara predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT fumiokumasawa predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT junkoteradahirashima predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT masayukihojo predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT kazuyukichibana predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma AT etsukotagaya predictingdupilumabeffectivenesswithtype2biomarkersarealworldstudyofsevereasthma |